Teladoc Health turns out a steep \$3.1B loss in Q2 how much finger-pointing goes to Livongo?

Article



The news: Teladoc Health announced a steep loss of \$3.1 billion in Q2.





- Teladoc posted a net loss of \$3.1 billion or \$19.22 per share for Q2 2022 compared with \$133.8 million or \$0.86 per share in Q2 2021.
- Teladoc reported a \$3 billion non-cash goodwill impairment charge for Q2 2022 and close to \$10 billion in impairment charges for the first half of 2022.

Putting the numbers in context: Teladoc's impairment charge is likely a result of its acquisition of digital therapeutics company Livongo in 2020.


- Teladoc bought Livongo to consolidate an app that offers primary care, chronic care, and telehealth, per Fierce Healthcare. However, Teladoc may have overpaid in its \$13.9 billion Livongo acquisition.
- As the US GDP <u>shrank</u> for the second consecutive quarter, sparking recession fears, Teladoc CEO Jason Gorevic acknowledged "increased uncertainty in the macroeconomic backdrop" affecting the company's earnings.

For context, Teladoc also posted a loss in Q1 2022.

The silver lining: Teladoc showed progress for its Primary 360 business, which the company says recently added new clients and capabilities.

- In addition, Teladoc's overall revenues increased 18% to \$592.4 million from \$503.1 million in the second quarter of 2021.
- And Teladoc expects positive results from its Chronic Care Complete business, which launched in February.

Teladoc has also <u>received</u> industry praise for its robust telehealth capabilities. And although telehealth has experienced a drop-off after the beginning of the COVID-19 pandemic, we expect the **number of telehealth users to grow to 116.6 million in 2025 versus 99.2 million in 2022**, according to our Telehealth Users <u>forecast</u>.



What's next? Teladoc expects results for the rest of 2022 to be on the lower end of its outlook. The company projects a fiscal year 2022 outlook range of \$2.4 billion to \$2.5 billion.